Expertise in
8
conditions

Yong Q. Fang

180 Fenglin Road, 
Zhongshan, CN 
Expertise in
8
conditions
180 Fenglin Road, 
Zhongshan, CN 

Overview

Yong Fang practices practicing medicine in Zhongshan, China.

Fang is highly rated in 8 conditions, according to our data. Their clinical expertise encompasses Gastrointestinal Stromal Tumor, Scrofula, Squamous Cell Lung Carcinoma, Gastrectomy, and Pancreaticoduodenectomy.

They are actively involved in clinical research, co-authoring 244 peer reviewed articles and participating in 5 clinical trials.

Locations

180 Fenglin Road, Zhongshan, China
Other Locations
28 Fuxing Road, Beijing, 100853, China
Sir Run Run Shaw Hospital, 3 East Qingchun Road, Hangzhou, 310016, China
180 Fenglin Road, Xuhui, 200032, China
No. 12 Middle Urumqi Road, Shanghai, 200040, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Multicenter, Open-label, Phase II Study With a Safety Lead-in Part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer Who Are BRAF- and MEK Inhibitor Treatment-naïve
Multicenter, Open-label, Phase II Study With a Safety Lead-in Part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer Who Are BRAF- and MEK Inhibitor Treatment-naïve
Enrollment Status: Active_not_recruiting
Publish Date: May 01, 2026
Intervention Type: Drug
Study Drugs: Encorafenib, Binimetinib
Study Phase: Phase 2
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: March 18, 2026
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
A Phase 3, Randomized, Open-label, Multicenter Study of the Efficacy and Safety of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) Harboring a HER2 Exon 20 Mutation Who Progressed on or After Treatment With Platinum Based Chemotherapy
Enrollment Status: Completed
Publish Date: December 19, 2025
Intervention Type: Drug
Study Drugs: Pyrotinib, Docetaxel
Study Phase: Phase 3
Multicenter, Open-label, Phase 1 Study Investigating the Safety and Tolerability of Encorafenib Monotherapy in BRAF V600E-mutated Chinese Patients With Advanced Metastatic Solid Tumors
Multicenter, Open-label, Phase 1 Study Investigating the Safety and Tolerability of Encorafenib Monotherapy in BRAF V600E-mutated Chinese Patients With Advanced Metastatic Solid Tumors
Enrollment Status: Completed
Publish Date: June 24, 2024
Intervention Type: Drug
Study Drug: Encorafenib
Study Phase: Phase 1
Safety, Tolerability and Partial Efficacy Study of a Personalized Neoantigen Cancer Vaccine inTreating Patients With Advanced Malignant Tumor
Safety, Tolerability and Partial Efficacy Study of a Personalized Neoantigen Cancer Vaccine inTreating Patients With Advanced Malignant Tumor
Enrollment Status: Unknown
Publish Date: November 16, 2021
Intervention Type: Other, Biological
Study Drugs: Granulocyte Colony-Stimulating Factor, Personalized Neoantigen Cancer Vaccine
Study Phase: Phase 1
View 4 Less Clinical Trials

244 Total Publications

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.
Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.
Journal: JAMA
Published: August 10, 2026

Frequently Asked Questions about Yong Q. Fang

Is Yong Q. Fang a top-rated expert for Gastrointestinal Stromal Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Yong Q. Fang is classified as an Distinguished expert for Gastrointestinal Stromal Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yong Q. Fang participate in research or clinical trials?

Yes. Yong Q. Fang has published 244 articles and abstracts on conditions like Gastrointestinal Stromal Tumor. You can view a list of Yong Q. Fang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Fang's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 33 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile